journal article·2026-01Open access

Computationally identified peptides immobilized to hydrogel delivery vehicles enable affinity-controlled release of proteins

Yuan Yao, Celestine Hong, Carter J. Teal, Noor E. Bahsoun, Sophia P. Lu, Ian Fernandes, Gordon Keller, Molly Shoichet

Acta Biomaterialia· Volume 210

Abstract

The administration of therapeutic proteins, such as growth factors, can be accomplished through affinity-based release systems, yet identifying suitable binding partners that achieve high protein loading and desirable release kinetics remains a significant challenge. In this work, we used a computationally guided approach to identify binding peptides for therapeutic proteins, significantly increasing the loading capacity of the functionalized hydrogel delivery platform. Using crystal structure data from the Protein Data Bank and Rosetta-based rational design, we extracted a 10 amino acid peptide segment from the heavy chain of bevacizumab to modulate the release of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Biolayer interferometry confirmed moderate binding affinity to VEGF (KD 10-5 M) and higher affinity for PDGF (KD 10-7 M). Mutational analysis revealed that aromatic residues were essential for binding. When covalently immobilized to a hyaluronan-methylcellulose hydrogel, the peptide enabled prolonged and sequential release of VEGF and PDGF. Computational modeling of the release kinetics using finite element analysis agreed with experimental data, validating the model and guiding the design of the delivery system. Importantly, the released proteins remained bioactive as demonstrated by cell growth and angiogenesis tube formation assays. This study demonstrates a simple and effective approach to achieve controlled and sequential release of therapeutic growth factors. STATEMENT OF SIGNIFICANCE: Proteins are promising therapeutics for multiple diseases; however, their delivery remains challenging due to the use of generic strategies, which often degrade the proteins. We used computational tools to identify specific binders for two growth factors (VEGF and PDGF), and then demonstrated the utility of these binders to control the release of bioactive proteins for a sustained period from a novel hydrogel. We achieved sequential release of VEGF followed by PDGF, which is important in vessel formation. This new system of identifying protein binding partners is broadly applicable and shown herein to be useful to control the release of two specific proteins. This combination of theoretical and experimental approaches is of broad interest to biomaterial researchers.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Hydrogels: synthesis, properties, applications · Supramolecular Self-Assembly in Materials · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (64)

Show source-provided references
1. Controlled release for local delivery of drugs: barriers and models10.1016/j.jconrel.2014.04.048 ↗
2. Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry10.1039/D3RA06476J ↗
3. Sustained release systems for delivery of therapeutic peptide/protein10.1021/acs.biomac.1c00160 ↗
4. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments10.1098/rsif.2010.0223 ↗
5. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release10.1021/acs.chemrev.5b00346 ↗
6. Long-term delivery of protein therapeutics10.1517/17425247.2015.961420 ↗
7. Leveraging affinity interactions to prolong drug delivery of protein therapeutics10.3390/pharmaceutics14051088 ↗
8. Mathematical model accurately predicts protein release from an affinity-based delivery system10.1016/j.jconrel.2014.10.032 ↗
9. Designer protein delivery: from natural to engineered affinity-controlled release systems10.1126/science.aac4750 ↗
10. Directed evolution: methodologies and applications10.1021/acs.chemrev.1c00260 ↗
11. Continuous directed evolution of proteins with improved soluble expression10.1038/s41589-018-0121-5 ↗
12. Affibody-mediated controlled release of fibroblast growth factor 210.1016/j.jconrel.2022.09.004 ↗
13. Directed evolution enables simultaneous controlled release of multiple therapeutic proteins from biopolymer-based hydrogels10.1002/adma.202202612 ↗
14. Engineering hydrogels for affinity-based release of therapeutic proteins10.1021/acs.chemmater.3c02242 ↗
15. Computational prediction of protein–protein binding affinities10.1002/wcms.1448 ↗
16. Predicting protein–Protein interactions from the molecular to the proteome level10.1021/acs.chemrev.5b00683 ↗
17. Binding affinity via docking: fact and fiction10.3390/molecules23081899 ↗
18. Prediction of protein–ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations10.1007/s10822-010-9363-3 ↗
19. A computational approach for designing D-proteins with non-canonical amino acid optimised binding affinity10.1371/journal.pone.0187524 ↗
20. Improving de novo protein binder design with deep learning10.1038/s41467-023-38328-5 ↗
21. Computational design of protein–protein interactions10.1016/j.sbi.2013.08.003 ↗
22. Peptiderive server: derive peptide inhibitors from protein–protein interactions10.1093/nar/gkw385 ↗
23. Can self-inhibitory peptides be derived from the interfaces of globular protein–protein interactions?10.1002/prot.22785 ↗
24. Rationally designed macrocyclic peptides as synergistic agonists of LPS-induced inflammatory response10.1016/j.tet.2014.07.026 ↗
25. In Silico insight into the dominant type II toxin–Antitoxin systems and clp proteases in Listeria monocytogenes and designation of derived peptides as a novel approach to interfere with this system10.1007/s10989-019-09868-6 ↗
26. Chapter 5 - role of growth factors and cytokines in therapeutic angiogenesis
27. Extracellular matrix and growth factor engineering for controlled angiogenesis in regenerative medicine10.3389/fbioe.2015.00045 ↗
28. Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis
29. PDGF and vessel maturation
30. Enhancing microvascular formation and vessel maturation through temporal control over multiple pro-angiogenic and pro-maturation factors10.1016/j.biomaterials.2013.08.007 ↗
31. Critical role of microenvironmental factors in angiogenesis10.1007/s11883-005-0011-7 ↗
32. Spatio–temporal VEGF and PDGF delivery patterns blood vessel formation and maturation10.1007/s11095-006-9173-4 ↗
33. Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB10.1096/fj.11-197400 ↗
34. Serverification of molecular modeling applications: the Rosetta online server that includes everyone (ROSIE)10.1371/journal.pone.0063906 ↗
35. Tunable growth factor delivery from injectable hydrogels for tissue engineering10.1021/ja210638x ↗
36. Affinity-controlled release of rod-derived cone viability factor enhances cone photoreceptor survival10.1016/j.actbio.2023.03.003 ↗
37. Development of rationally designed affinity-based drug delivery systems10.1016/j.actbio.2004.09.002 ↗
38. Tunable surface charge enables the electrostatic adsorption-controlled release of neuroprotective peptides from a hydrogel–Nanoparticle drug delivery system10.1021/acsami.2c17631 ↗
39. Generation of functional liver sinusoidal endothelial cells from Human pluripotent stem-cell-derived venous angioblasts10.1016/j.stem.2020.06.007 ↗
40. Therapeutic correction of hemophilia A by transplantation of hPSC-derived liver sinusoidal endothelial cell progenitors10.1016/j.celrep.2022.110621 ↗
41. Angiogenesis Analyzer for ImageJ — A comparative morphometric analysis of “endothelial tube formation assay” and “fibrin bead assay”10.1038/s41598-020-67289-8 ↗
42. M. Christie, R. Rouet, D. Nevoltris, D. Langley, P. Schofield, L. Fabri, K. Tingey, D. Lowe, L. Jermutus, D. Christ, Stable human IgG antibody therapeutics with native framework structure, (2017).
43. A structural overview of vascular endothelial growth factors pharmacological ligands: from macromolecules to designed peptidomimetics10.3390/molecules26226759 ↗
44. Vascular endothelial growth factor (VEGF) as a target of Bevacizumab in cancer: from the biology to the clinic10.2174/092986706777585059 ↗
45. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site10.1126/science.1165480 ↗
46. Structure of the full-length VEGFR-1 extracellular domain in complex with VEGF-A10.1016/j.str.2016.12.012 ↗
47. Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization10.1182/blood-2011-11-390922 ↗
48. Characterization of binding mode of action of a blocking anti-platelet-derived growth factor (PDGF)-B monoclonal antibody, MOR8457, reveals conformational flexibility and avidity needed for PDGF-BB to bind PDGF receptor-β10.1021/bi5015425 ↗
49. Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition10.1073/pnas.0401786101 ↗
50. The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies10.1016/j.jmb.2008.01.093 ↗
51. Affibody-mediated controlled release of fibroblast growth factor 210.1016/j.jconrel.2022.09.004 ↗
52. Design of target specific peptide inhibitors using generative deep learning and molecular dynamics simulations10.1038/s41467-024-45766-2 ↗
53. De novo design of high-affinity binders of bioactive helical peptides10.1038/s41586-023-06953-1 ↗
54. Diffusion and viscosity in mixed protein solutions10.1021/acs.jpcb.4c06877 ↗
55. Protein charge and mass contribute to the spatio-temporal dynamics of protein-protein interactions in a minimal proteome10.1002/pmic.201100540 ↗
56. Function, structure, and stability of enzymes confined in Agarose gels10.1371/journal.pone.0086785 ↗
57. Combined effects of confinement and macromolecular crowding on protein stability10.3390/ijms21228516 ↗
58. Evolutionary capacitance and control of protein stability in protein-protein interaction networks10.1371/journal.pcbi.1003023 ↗
59. Analysis of conformational stability of interacting residues in protein binding interfaces
60. Adhesive protein-based angiogenesis-mimicking spatiotemporal sequential release of angiogenic factors for functional regenerative medicine10.1016/j.biomaterials.2021.120774 ↗
61. How does temporal and sequential delivery of multiple growth factors affect vascularization inside 3D hydrogels?
62. Sequential delivery of VEGF, FGF-2 and PDGF from the polymeric system enhance HUVECs angiogenesis in vitro and CAM angiogenesis10.1016/j.cellimm.2017.10.008 ↗
63. Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction10.1016/j.jconrel.2015.03.034 ↗
64. Injectable polymeric delivery system for spatiotemporal and sequential release of therapeutic proteins to promote therapeutic angiogenesis and reduce inflammation10.1021/acsbiomaterials.9b01758 ↗